BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 15560531)

  • 1. Diagnostic value of CA 15-3 antibody in detecting metastatic adenocarcinoma.
    Huang Y; Zimmerman RL; Bibbo M
    Anal Quant Cytol Histol; 2004 Oct; 26(5):259-62. PubMed ID: 15560531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of a second generation CA 15-3 antibody to detect adenocarcinoma in body cavity effusions.
    Zimmerman RL; Fogt F; Goonewardene S
    Cancer; 2000 Aug; 90(4):230-4. PubMed ID: 10966563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
    Shield PW; Papadimos DJ; Walsh MD
    Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GLUT1 antibody staining in thin-layer specimens of benign and malignant body cavity effusions.
    Mensch LS; Weller L; Simmons-Arnold L; Gibson PC; Leiman G; Beatty B
    Acta Cytol; 2002; 46(5):813-8. PubMed ID: 12365212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids.
    Afify A; Zhou H; Howell L; Paulino AF
    Acta Cytol; 2005; 49(6):621-6. PubMed ID: 16450901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic utility of BCA-225 in detecting adenocarcinoma in serous effusions.
    Zimmerman RL; Fogt F; Goonewardene S
    Anal Quant Cytol Histol; 2000 Oct; 22(5):353-7. PubMed ID: 11064810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of immunocytochemical expression of E-cadherin, N-cadherin and CD44 in serous effusions using liquid-based cytology.
    Malle D; Valeri RM; Photiou C; Kaplanis K; Andreadis C; Tsavdaridis D; Destouni C
    Acta Cytol; 2005; 49(1):11-6. PubMed ID: 15717748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Podoplanin is a useful marker for identifying mesothelioma in malignant effusions.
    Hanna A; Pang Y; Bedrossian CW; Dejmek A; Michael CW
    Diagn Cytopathol; 2010 Apr; 38(4):264-9. PubMed ID: 20146302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions.
    Zhu W; Michael CW
    Diagn Cytopathol; 2007 Jun; 35(6):370-5. PubMed ID: 17497661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucose transporter Glut-1 is of limited value for detecting breast carcinoma in serous effusions.
    Zimmerman RL; Goonewardene S; Fogt F
    Mod Pathol; 2001 Aug; 14(8):748-51. PubMed ID: 11504833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the primary site of metastatic adenocarcinoma in serous effusions. Value of an immunocytochemical panel added to the clinical arsenal.
    Longatto Filho A; Alves VA; Kanamura CT; Nonogaki S; Bortolan J; Lombardo V; Bisi H
    Acta Cytol; 2002; 46(4):651-8. PubMed ID: 12146025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble oncoprotein 185HER-2 in pleural fluid has limited usefulness for the diagnostic evaluation of malignant effusions.
    Porcel JM; Salud A; Vives M; Esquerda A; Rodríguez-Panadero F
    Clin Biochem; 2005 Nov; 38(11):1031-3. PubMed ID: 15925354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions:: A Cell-Block Microarray Study.
    El Hag MI; Ha J; Farag R; El Hag AM; Michael CW
    Diagn Cytopathol; 2016 Sep; 44(9):731-6. PubMed ID: 27338760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic usefulness of MUC1 and MUC4 for distinguishing between metastatic adenocarcinoma cells and reactive mesothelial cells in effusion cell blocks.
    Cho JS; Kim GE; Lee JS; Lee JH; Nam JH; Choi C
    Acta Cytol; 2013; 57(4):377-83. PubMed ID: 23860190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
    Ylagan LR; Zhai J
    Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wilms tumor 1/cytokeratin dual-color immunostaining reveals distinctive staining patterns in metastatic melanoma, metastatic carcinoma, and mesothelial cells in pleural fluids: an effective first-line test for the workup of malignant effusions.
    Conner JR; Cibas ES; Hornick JL; Qian X
    Cancer Cytopathol; 2014 Aug; 122(8):586-95. PubMed ID: 25044880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mammaglobin and CRxA-01 in pleural effusion cytology: potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas.
    Ciampa A; Fanger G; Khan A; Rock KL; Xu B
    Cancer; 2004 Dec; 102(6):368-72. PubMed ID: 15558786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic utility of sialosyl-Tn in discriminating carcinomatous cells from benign mesothelium in body cavity effusions.
    Zimmerman RL; Fogt F; Bibbo M
    Acta Cytol; 1999; 43(6):1079-84. PubMed ID: 10578981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.
    Porcel JM; Vives M; Esquerda A; Salud A; Pérez B; Rodríguez-Panadero F
    Chest; 2004 Dec; 126(6):1757-63. PubMed ID: 15596670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.